Skip to main content

Advances in Cancer Research

  • 1st Edition, Volume 85 - September 30, 2002
  • Latest edition
  • Editors: George F. Vande Woude, George Klein
  • Language: English

Data Mining & ML

Unlock the cutting edge

Up to 20% on trusted resources. Build expertise with data mining, ML methods.

Readership

Researchers and students in the basic and clinical science of cancer biology and oncology, genetics, immunology, pharmacology, cell and molecular biology.

Table of contents

The Von Hippel-Lindau Tumor Suppressor Complex and Regulation of Hypoxia-Inducible Transcription. Retinoblastoma Tumor Suppressor and Genome Stability.
The Abl Family Kinases: Mechanisms of Regulation and Signaling.
Cellular Immunity to the Her-2/neu Proto-oncogene.
A New Challenge for Successful Immunotherapy by Tumors That Are Resistant to Apoptosis: Two Complementary Signals to Overcome Cross-Resistance.
Cell Volume and Ion Changes During Apoptotic Cell Death.
Mitochondria and Apoptosis: New Therapeutic Targets.

Review quotes

PRAISE FOR THE SERIES
"This classic and essential series presents critical overviews on select aspects of both cancer research and the basic underlying sciences."—AMERICAN SCIENTIST

"Excellent, highly informative, in-depth reviews...expertly written,
up-to-date, and well-referenced."—JOURNAL OF MEDICINAL CHEMISTRY

"This is a series that has a long tradition of excellence in the field of cancer biology."—DOODY'S PUBLISHING REVIEWS

Product details

  • Edition: 1
  • Latest edition
  • Volume: 85
  • Published: October 16, 2002
  • Language: English

About the editors

GV

George F. Vande Woude

Affiliations and expertise
Director, Van Andel Research Institute, Grand Rapids, MI, USA NCI-Frederick Cancer Research Facility Frederick, Maryland ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland

GK

George Klein

Affiliations and expertise
Karolinska Insitutet, Stockholm, Sweden

View book on ScienceDirect

Read Advances in Cancer Research on ScienceDirect